SlideShare une entreprise Scribd logo
1  sur  37
Télécharger pour lire hors ligne
A SEMINOR ON
BIO PHARMACEUTICS
CLASSIFICATION SYSTEM
BY
P. HARI BABU
MPHARMACY
NALANDA COLLEGE OF
PHARMACEUTICAL SCINCE
Contents
• Introduction
• Overview of the Classification
system
• Applications
• Conclusion
• References
Introduction
Biopharmaceutics Classification
System (BCS)
♥Scientific framework for classifying drug
substances based on their aqueous solubility and
intestinal permeability
 What is the need for a classification
based on biopharmaceutics of the
drug?
• Ans. Its importance in determining
bioavailability
♠ Route of choice for the formulators
 Continues to dominate the area of drug delivery
technologies.
 LIMITATIONS
 Absorption and Bioavailability in the milieu of
gastrointestinal tract.
 Limitations more prominent
 with the advent of protein and peptide drugs
 compounds emerging as a result of combinatorial chemistry and
the technique of high throughput screening
ORAL ROUTE
drug
solubility
drug product
quality
attributes
API structure
salt form and
excipients
Bioavailability of drug
is determined by
extent of drug solubility
and
permeability
 Guidance provided by the U.S. Food and Drug
Administration for predicting the intestinal drug
absorption
The fundamental basis established by
Dr. Gordon Amidon
 Distinguished Science Award (Aug ’06 ,FIP)
 First introduced into regulatory decision-making process in the
guidance document on Immediate Release Solid Oral Dosage
Forms: Scale Up And Post Approval Changes
Biopharmaceutics Classification System
 Drug development tool that allows estimation of the
contributions of 3 major factors, that affect
oral drug absorption from immediate release
solid oral dosage forms
Dissolution
Solubility
Intestinal permeability.
The Biopharmaceutics Classification System (BCS)
(as defined by the FDA after Amidon)
SIMILAR IN VIVO
DISSOLUTION
SIMILAR IN VIVO ABSORPTION
SIMILAR SYSTEMIC
AVAILABILITY
Dissolution of drug in vivo
Drug Concentration in
the Membrane Domain
Intestinal Absorption
determines
proportional
Basis of BCS
(37±100
C in aqueous medium with pH range of 1-7.5.)
A sufficient number of pH conditions
 ionization characteristics of the test drug substance
A minimum of three replicate determinations of
solubility in each pH condition
 Standard buffer solutions described in pharmacopoeias
Methods other than shake flask method (with
Justification). e g. acid or base titration methods
SOLUBILITY DETERMINATION
♣ Not just based on lipophilicity (encompass in vivo effects
of efflux and uptake transporters)
A. Human studies
 Mass balance studies
 Absolute bioavailability studies
 Intestinal perfusion methods
B.In vivo or in situ intestinal perfusion in a suitable animal
model
C.In vitro permeability methods using excised intestinal
tissues
D. In vitro permeation studies across a monolayer of cultured
epithelial cells.e.g. Caco-2 cells or TC-7 cells
Determination
of permeability
DISSOLUTION DETERMINATION
 USP apparatus I (basket) at 100 rpm or USP apparatus
II (paddle) at 50 rpm.
 Dissolution media (900 ml): 0.1 N HCl or simulated
gastric fluid, pH 4.5 buffer, and pH 6.8 buffer or
simulated intestinal fluid.
 Compare dissolution profiles of test and reference
products using a similarity factor (f2).
0
CLASS BOUNDARIES
HIGHLY SOLUBLE the highest dose strength is
soluble in < 250 ml water over a pH range of 1 to 7.5.
The volume estimate-a glassful (8 ounce)
HIGHLY PERMEABLE when the extent of
absorption in humans is determined to be > 90% of
an administered dose
RAPIDLY DISSOLVING when > 85% of the
labeled amount of drug substance dissolves within 30
minutes using USP apparatus I or II in a volume of <
900 ml buffer solutions.
BCS Class Boundaries: Objectives
Dissolution
(Product)
Solubility
(Drug)
Permeabilit
y
(Drug)
Rapid dissolution - ensure that in vivo
dissolution is not likely to be the
“rate determining” step
High solubility- ensure that solubility
is not likely to limit dissolution and,
therefore, absorption
High permeability - ensure that drug
is completely absorbed during the limited
transit time through the small intestine
Bcs classification system
BCS -Implications for drug
developmentЖApplication in early drug development and then in
the management of product change through its life
cycle
ЖAids fundamental understanding of the
biopharmaceutical and physical properties of the drug
ЖAids discriminatory dissolution method development
ЖCan help guide the development of in-vitro/in-vivo
correlations
ЖCan be used to obtain a biowaiver
ЖDevelopment of poorly soluble drugs
This classification is associated with drug
dissolution and absorption model, which
identifies the key parameters controlling
drug absorption as a set of dimensionless
numbers viz
BCS defines 3 numbers (no units)
An ~ absorption number
Do ~ dose number
Dn ~ dissolution number
( )
ABS
GI
GI
eff
T
T
T
R
P
An =





=
Effective permeability
Radius of GI
Residence time in GI
Time required for
complete absorption
Absorption Number
A function of GI Permeability to Drug Substance










=
S
Water
C
V
D
Do
Highest Dose Unit
250 mL
Solubility
Dose Number
A function of solubility of drug substance
Solubility
mg/mL
( ) 





=










=
DISS
GI
GI
S
T
T
T
C
r
D
Dn
ρ2
3
Diffusivity
5x10-6
cm2
/s
Density
1.2 mg/cm3
Particle Radius
25 µm
Residence time in GI
180 min
Time required for
complete dissolution
Dissolution Number
A function of drug release from formulation
Bcs classification system
IVIVC expectations for immediate release products based on
BCS
Class Solubility Permeability Absorption
rate
control
IVIVC expectations for
Immediate release product
I High High Gastric
emptying
IVIVC expected, if dissolution rate is
slower than gastric emptying rate,
otherwise limited or no
correlations
II Low High Dissolution IVIVC expected, if in vitro
dissolution rate is similar to in
vivo dissolution rate, unless
dose is very high.
III High Low Permeability Absorption (permeability) is rate
determining and limited or no
IVIVC with dissolution.
IV Low Low Case by
case
Limited or no IVIVC is expected.
High Solubility Low SolubilityHighPermeability
Class 1
Abacavir
Acetaminophen
Acyclovirb
AmilorideS,I
Amitryptyline S,I
Antipyrine
Atropine
Buspironec
Caffeine
Captopril
ChloroquineS,I
Chlorpheniramine
Cyclophosphamide
Desipramine
Diazepam
Diltiazem S,I
Diphenhydramine
Disopyramide
Doxepin
Doxycycline
Enalapril
Ephedrine
Ergonovine
Ethambutol
Ethinyl Estradiol
FluoxetineI
Glucose
ImipramineI
Ketorolac
Ketoprofen
Labetolol
LevodopaS
Levofloxacin S
LidocaineI
Lomefloxacin
Meperidine
Metoprolol
Metronidazole
MidazolamS,I
Minocycline
Misoprostol
Nifedipine S
Phenobarbital
Phenylalanine
Prednisolone
PrimaquineS
Promazine
Propranolol I
Quinidine
S,I
Rosiglitazone
Salicylic acid
Theophylline
Valproic acid
Verapamil I
Zidovudine
Class 2
Amiodarone I
AtorvastatinS, I
AzithromycinS ,I
Carbamazepine S,I
Carvedilol
Chlorpromazine I
CisaprideS
Ciprofloxacin S
Cyclosporine
S, I
Danazol
Dapsone
Diclofenac
Diflunisal
Digoxin S
Erythromycin S,I
Flurbiprofen
Glipizide
GlyburideS,I
Griseofulvin
Ibuprofen
Indinavir S
Indomethacin
Itraconazole S,I
Ketoconazole I
LansoprazoleI
Lovastatin S,I
Mebendazole
Naproxen
Nelfinavir S,I
Ofloxacin
Oxaprozin
Phenazopyridine
PhenytoinS
Piroxicam
Raloxifene S
Ritonavir S,I
Saquinavir S,I
Sirolimus S
Spironolactone I
Tacrolimus S,I
TalinololS
Tamoxifen I
Terfenadine I
Warfarin
High Solubility Low SolubilityLowPermeability
Class 3
Acyclovir
AmilorideS,I
AmoxicillinS,I
Atenolol
Atropine
Bisphosphonates
Bidisomide
Captopril
Cefazolin
Cetirizine
Cimetidine S
CiprofloxacinS
Cloxacillin
DicloxacillinS
ErythromycinS,I
Famotidine
FexofenadineS
Folinic acid
Furosemide
Ganciclovir
Hydrochlorothiazide
Lisinopril
Metformin
Methotrexate
Nadolol
PravastatinS
Penicillins
RanitidineS
Tetracycline
TrimethoprimS
Valsartan
Zalcitabine
Class 4
Amphotericin B
Chlorthalidone
Chlorothiazide
Colistin
CiprofloxacinS
Furosemide
Hydrochlorothiazide
Mebendazole
Methotrexate
Neomycin
Applications of BCS in oral drug
delivery technology
 Achieve a target release profile associated with a
particular pharmacokinetic and/or pharmacodynamic
profile.
 Formulation approaches include both control of release
rate and certain physicochemical properties of drugs
like pH-solubility profile of drug.
Class I - High Permeability,
High Solubility
Class II - High Permeability,
Low Solubility
Micronisation,
Addition of surfactants,
Formulation as emulsions and microemulsions
systems,
Use of complexing agents like cyclodextrins
 Require the technologies that address to
fundamental limitations of absolute or
regional permeability.
 Peptides and proteins constitute the part of
class III and the technologies handling such
materials are on rise now days
Class III - Low Permeability,
High Solubility
Class IV - Low Permeability,
Low Solubility
♫Major challenge for development of drug
delivery system and the route of choice
for administering such drugs is parenteral
(solubility enhancers.)
♫Fortunately, extreme examples are the
exception rather than the rule and are
rarely developed and reach the market
Biowaiver
 A biowaiver is an exemption from conducting
human bioequivalence studies when the active
ingredient(s) meet certain solubility and
permeability criteria in vitro and when the
dissolution profile of the dosage form meets the
requirements for an "immediate" release dosage
form.
Waiver of In Vivo Bioequivalence Study
based on
Pharmaceutical Dosage Form (Solutions)
Biopharmaceutics Classification
System
Dose. (Highest Strength should be tested)
BCS BIOWAIVER
 Biowaiver for
 Rapid and similar dissolution.
 High solubility &High permeability.
 Wide therapeutic window.
 Excipients used in dosage form used
previously in approved IR solid dosage
forms.
REQUEST FOR BIOWAIVERS
Data Supporting :-
Rapid and Similar Dissolution
High Permeability
High Solubility
Limitations of BCS as a Predictor
of Drug Disposition
Ω Permeability (90% absorption) is difficult to
determine, and difficult to convince the regulatory
agency .
Ω There is little predictability for BCS classification
drugs beyond Class 1 primarily due to the difficulty of
determining and proving 90% absorption.
 many drugs are misclassified (e.g. HIV protease inhibitors
as Class 4 compounds)).
Conclusion
 BCS aims to provide a regulatory tool for
replacing certain BE studies by accurate in-
vitro dissolution tests..
 This increased awareness of a proper
biopharmaceutical characterization of new
drugs may in the future result in drug
molecules with a sufficiently high
permeability, solubility and dissolution rate,
and that will automatically increase the
importance of the BCS as a regulatory tool
over time
References:
 Draft guidance for industry, waiver of in vivo bioavailability
and bioequivalence studies for immediate release solid oral
dosage forms containing certain active moieties/ active
ingredients based on a biopharmaceutic classification system,
february 1999, CDER/FDA.
 Amidon G.L., Lennernas H., Shah V.P., Crison J.R.A., A
theoretical basis for a biopharmaceutic drug classification:
the correlation of in vitro drug product dissolution and in
vivo bioavailability. Pharm. Res. 12: 413-420 (1995).
 Guidance for industry, immediate release solid oral dosage
forms: scale up and post approval changes, november 1995,
CDER/FDA.
 Medicamento generico from website
http://www.Anvisa.Go/.
 Devane J., Oral drug delivery technology: addressing the solubility/
permeability paradigm, pharm. Technol. 68-74, november 1998
 Amidon, G. L.,Lennernäs H., Shah V. P., And crisonj. R., A theoretical
basis for a biopharmaceutics drug classification: the correlation of in
vitro drug product dissolution and in vivo bioavailability,
Pharmaceutical research, 12: 413-420 (1995)
 Guidance for Industry: Dissolution Testing of Immediate Release Solid
Oral Dosage Forms, FDA CDER, 1997
􀀛http://www.fda.gov/cder/guidance/1713bp1.pdf
 Guidance for Industry: Waiver of In Vivo Bioavailability and
Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms
Based on a Biopharmaceutics Classification System, FDA CDER,
August 2000 http://www.fda.gov/cder/guidance/3618fnl.htm
Thank you..

Contenu connexe

Tendances

Preparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsPreparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsROHIT
 
Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability Anindya Jana
 
Gastroretentive Drug Delivery System
Gastroretentive Drug Delivery SystemGastroretentive Drug Delivery System
Gastroretentive Drug Delivery SystemNone
 
Feedback regulated drug delivery system
Feedback regulated drug delivery systemFeedback regulated drug delivery system
Feedback regulated drug delivery systemSurbhi Narang
 
oral controlled drug delivery system
oral controlled drug delivery systemoral controlled drug delivery system
oral controlled drug delivery systemBaliram Musale
 
SUSTAINED RELEASE DOSAGE FORMULATION
SUSTAINED RELEASE DOSAGE FORMULATIONSUSTAINED RELEASE DOSAGE FORMULATION
SUSTAINED RELEASE DOSAGE FORMULATIONGOKULAKRISHNAN S
 
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGNBIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGNN Anusha
 
Biopharmaceutical Classification System
 Biopharmaceutical Classification System Biopharmaceutical Classification System
Biopharmaceutical Classification SystemVaishnaviBhosale6
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification systemReshma Fathima .K
 
Feedback Regulated Drug Delivery System
Feedback Regulated Drug Delivery SystemFeedback Regulated Drug Delivery System
Feedback Regulated Drug Delivery Systemkuldip aghera
 
Techniques for enhancement of dissolution rate
Techniques for enhancement of dissolution rateTechniques for enhancement of dissolution rate
Techniques for enhancement of dissolution rateSagar Savale
 
M pharm dissolution
M pharm dissolutionM pharm dissolution
M pharm dissolutionceutics1315
 
Sustained release dds by vidya
Sustained release dds by vidyaSustained release dds by vidya
Sustained release dds by vidyasrividya gorantla
 
DISSOLUTION PARAMETERS AND ITS APPARATUS
DISSOLUTION PARAMETERS AND ITS APPARATUSDISSOLUTION PARAMETERS AND ITS APPARATUS
DISSOLUTION PARAMETERS AND ITS APPARATUSROHIT
 
SUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power pointSUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power pointSonam Gandhi
 

Tendances (20)

Preparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsPreparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentrals
 
Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability
 
Gastroretentive Drug Delivery System
Gastroretentive Drug Delivery SystemGastroretentive Drug Delivery System
Gastroretentive Drug Delivery System
 
Feedback regulated drug delivery system
Feedback regulated drug delivery systemFeedback regulated drug delivery system
Feedback regulated drug delivery system
 
oral controlled drug delivery system
oral controlled drug delivery systemoral controlled drug delivery system
oral controlled drug delivery system
 
SUSTAINED RELEASE DOSAGE FORMULATION
SUSTAINED RELEASE DOSAGE FORMULATIONSUSTAINED RELEASE DOSAGE FORMULATION
SUSTAINED RELEASE DOSAGE FORMULATION
 
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGNBIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
 
Biopharmaceutical Classification System
 Biopharmaceutical Classification System Biopharmaceutical Classification System
Biopharmaceutical Classification System
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
 
Feedback Regulated Drug Delivery System
Feedback Regulated Drug Delivery SystemFeedback Regulated Drug Delivery System
Feedback Regulated Drug Delivery System
 
Mucoadhesive dds
Mucoadhesive ddsMucoadhesive dds
Mucoadhesive dds
 
Techniques for enhancement of dissolution rate
Techniques for enhancement of dissolution rateTechniques for enhancement of dissolution rate
Techniques for enhancement of dissolution rate
 
Dissolution
DissolutionDissolution
Dissolution
 
M pharm dissolution
M pharm dissolutionM pharm dissolution
M pharm dissolution
 
Sustained release dds by vidya
Sustained release dds by vidyaSustained release dds by vidya
Sustained release dds by vidya
 
DISSOLUTION PARAMETERS AND ITS APPARATUS
DISSOLUTION PARAMETERS AND ITS APPARATUSDISSOLUTION PARAMETERS AND ITS APPARATUS
DISSOLUTION PARAMETERS AND ITS APPARATUS
 
Dissolution methods
Dissolution methodsDissolution methods
Dissolution methods
 
Biowaivers
BiowaiversBiowaivers
Biowaivers
 
Controlled Release Oral Drug Delivery System
Controlled Release Oral Drug Delivery SystemControlled Release Oral Drug Delivery System
Controlled Release Oral Drug Delivery System
 
SUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power pointSUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power point
 

Similaire à Bcs classification system

BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics Hemant Khandoliya
 
Biopharmaceutics classification system class 1
Biopharmaceutics classification system class 1Biopharmaceutics classification system class 1
Biopharmaceutics classification system class 1Aloysiatreslyn
 
Biopharmaceutical classification system.
Biopharmaceutical classification system.Biopharmaceutical classification system.
Biopharmaceutical classification system.Smritibhanu
 
Bcs classification by sneha gaurkar
Bcs classification by sneha gaurkarBcs classification by sneha gaurkar
Bcs classification by sneha gaurkarSneha Gaurkar
 
bio availability
bio availabilitybio availability
bio availabilityPrem Sai
 
biopharmaceuticals classification system and biowaiver
biopharmaceuticals classification system and biowaiverbiopharmaceuticals classification system and biowaiver
biopharmaceuticals classification system and biowaiverRavish Yadav
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification systemAzka Shakeeb
 
BCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdfBCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdfAsif Shaikh
 
BCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptxBCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptxNishaN19p7504
 
biopharmaceuticalclassificationystembcs-160328061345.pdf
biopharmaceuticalclassificationystembcs-160328061345.pdfbiopharmaceuticalclassificationystembcs-160328061345.pdf
biopharmaceuticalclassificationystembcs-160328061345.pdfNishaN19p7504
 
Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Sagar Savale
 
Bioavailability and Bioequivalence study
Bioavailability and Bioequivalence studyBioavailability and Bioequivalence study
Bioavailability and Bioequivalence studyMcpl Moshi
 
Bioavailability and bioequivalence study
Bioavailability and bioequivalence studyBioavailability and bioequivalence study
Bioavailability and bioequivalence studyMcpl Moshi
 
Bioavailability, Bioequivalence and BCS Classification
Bioavailability, Bioequivalence and BCS ClassificationBioavailability, Bioequivalence and BCS Classification
Bioavailability, Bioequivalence and BCS ClassificationVignan University
 
Biopharmaceutical classification system
Biopharmaceutical classification systemBiopharmaceutical classification system
Biopharmaceutical classification systemArpitha Aarushi
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification systemAshwani Kumar Singh
 

Similaire à Bcs classification system (20)

BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics BCS classification system : Applications in pharmaceutics
BCS classification system : Applications in pharmaceutics
 
Bcs classification system
Bcs classification system Bcs classification system
Bcs classification system
 
Biopharmaceutics classification system class 1
Biopharmaceutics classification system class 1Biopharmaceutics classification system class 1
Biopharmaceutics classification system class 1
 
Biopharmaceutical classification system.
Biopharmaceutical classification system.Biopharmaceutical classification system.
Biopharmaceutical classification system.
 
Bcs classification by sneha gaurkar
Bcs classification by sneha gaurkarBcs classification by sneha gaurkar
Bcs classification by sneha gaurkar
 
Ba&be new'
Ba&be new'Ba&be new'
Ba&be new'
 
bio availability
bio availabilitybio availability
bio availability
 
biopharmaceuticals classification system and biowaiver
biopharmaceuticals classification system and biowaiverbiopharmaceuticals classification system and biowaiver
biopharmaceuticals classification system and biowaiver
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
 
BCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdfBCS , biowaeverAsif.pdf
BCS , biowaeverAsif.pdf
 
BCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptxBCS classification (SHETTY CHETHAN).pptx
BCS classification (SHETTY CHETHAN).pptx
 
08 (1681 1690)
08 (1681 1690)08 (1681 1690)
08 (1681 1690)
 
biopharmaceuticalclassificationystembcs-160328061345.pdf
biopharmaceuticalclassificationystembcs-160328061345.pdfbiopharmaceuticalclassificationystembcs-160328061345.pdf
biopharmaceuticalclassificationystembcs-160328061345.pdf
 
Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]Bio pharmaceutical classification System [BCS]
Bio pharmaceutical classification System [BCS]
 
Bioavailability and Bioequivalence study
Bioavailability and Bioequivalence studyBioavailability and Bioequivalence study
Bioavailability and Bioequivalence study
 
Bioavailability and bioequivalence study
Bioavailability and bioequivalence studyBioavailability and bioequivalence study
Bioavailability and bioequivalence study
 
Bioavailability, Bioequivalence and BCS Classification
Bioavailability, Bioequivalence and BCS ClassificationBioavailability, Bioequivalence and BCS Classification
Bioavailability, Bioequivalence and BCS Classification
 
Biopharmaceutical classification system
Biopharmaceutical classification systemBiopharmaceutical classification system
Biopharmaceutical classification system
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
 
Jatin ivivc
Jatin ivivcJatin ivivc
Jatin ivivc
 

Dernier

airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 

Dernier (20)

airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 

Bcs classification system

  • 1. A SEMINOR ON BIO PHARMACEUTICS CLASSIFICATION SYSTEM BY P. HARI BABU MPHARMACY NALANDA COLLEGE OF PHARMACEUTICAL SCINCE
  • 2. Contents • Introduction • Overview of the Classification system • Applications • Conclusion • References
  • 3. Introduction Biopharmaceutics Classification System (BCS) ♥Scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability  What is the need for a classification based on biopharmaceutics of the drug? • Ans. Its importance in determining bioavailability
  • 4. ♠ Route of choice for the formulators  Continues to dominate the area of drug delivery technologies.  LIMITATIONS  Absorption and Bioavailability in the milieu of gastrointestinal tract.  Limitations more prominent  with the advent of protein and peptide drugs  compounds emerging as a result of combinatorial chemistry and the technique of high throughput screening ORAL ROUTE
  • 5. drug solubility drug product quality attributes API structure salt form and excipients Bioavailability of drug is determined by extent of drug solubility and permeability
  • 6.  Guidance provided by the U.S. Food and Drug Administration for predicting the intestinal drug absorption The fundamental basis established by Dr. Gordon Amidon  Distinguished Science Award (Aug ’06 ,FIP)  First introduced into regulatory decision-making process in the guidance document on Immediate Release Solid Oral Dosage Forms: Scale Up And Post Approval Changes Biopharmaceutics Classification System
  • 7.  Drug development tool that allows estimation of the contributions of 3 major factors, that affect oral drug absorption from immediate release solid oral dosage forms Dissolution Solubility Intestinal permeability.
  • 8. The Biopharmaceutics Classification System (BCS) (as defined by the FDA after Amidon)
  • 9. SIMILAR IN VIVO DISSOLUTION SIMILAR IN VIVO ABSORPTION SIMILAR SYSTEMIC AVAILABILITY Dissolution of drug in vivo Drug Concentration in the Membrane Domain Intestinal Absorption determines proportional Basis of BCS
  • 10. (37±100 C in aqueous medium with pH range of 1-7.5.) A sufficient number of pH conditions  ionization characteristics of the test drug substance A minimum of three replicate determinations of solubility in each pH condition  Standard buffer solutions described in pharmacopoeias Methods other than shake flask method (with Justification). e g. acid or base titration methods SOLUBILITY DETERMINATION
  • 11. ♣ Not just based on lipophilicity (encompass in vivo effects of efflux and uptake transporters) A. Human studies  Mass balance studies  Absolute bioavailability studies  Intestinal perfusion methods B.In vivo or in situ intestinal perfusion in a suitable animal model C.In vitro permeability methods using excised intestinal tissues D. In vitro permeation studies across a monolayer of cultured epithelial cells.e.g. Caco-2 cells or TC-7 cells Determination of permeability
  • 12. DISSOLUTION DETERMINATION  USP apparatus I (basket) at 100 rpm or USP apparatus II (paddle) at 50 rpm.  Dissolution media (900 ml): 0.1 N HCl or simulated gastric fluid, pH 4.5 buffer, and pH 6.8 buffer or simulated intestinal fluid.  Compare dissolution profiles of test and reference products using a similarity factor (f2). 0
  • 13. CLASS BOUNDARIES HIGHLY SOLUBLE the highest dose strength is soluble in < 250 ml water over a pH range of 1 to 7.5. The volume estimate-a glassful (8 ounce) HIGHLY PERMEABLE when the extent of absorption in humans is determined to be > 90% of an administered dose RAPIDLY DISSOLVING when > 85% of the labeled amount of drug substance dissolves within 30 minutes using USP apparatus I or II in a volume of < 900 ml buffer solutions.
  • 14. BCS Class Boundaries: Objectives Dissolution (Product) Solubility (Drug) Permeabilit y (Drug) Rapid dissolution - ensure that in vivo dissolution is not likely to be the “rate determining” step High solubility- ensure that solubility is not likely to limit dissolution and, therefore, absorption High permeability - ensure that drug is completely absorbed during the limited transit time through the small intestine
  • 16. BCS -Implications for drug developmentЖApplication in early drug development and then in the management of product change through its life cycle ЖAids fundamental understanding of the biopharmaceutical and physical properties of the drug ЖAids discriminatory dissolution method development ЖCan help guide the development of in-vitro/in-vivo correlations ЖCan be used to obtain a biowaiver ЖDevelopment of poorly soluble drugs
  • 17. This classification is associated with drug dissolution and absorption model, which identifies the key parameters controlling drug absorption as a set of dimensionless numbers viz BCS defines 3 numbers (no units) An ~ absorption number Do ~ dose number Dn ~ dissolution number
  • 18. ( ) ABS GI GI eff T T T R P An =      = Effective permeability Radius of GI Residence time in GI Time required for complete absorption Absorption Number A function of GI Permeability to Drug Substance
  • 19.           = S Water C V D Do Highest Dose Unit 250 mL Solubility Dose Number A function of solubility of drug substance
  • 20. Solubility mg/mL ( )       =           = DISS GI GI S T T T C r D Dn ρ2 3 Diffusivity 5x10-6 cm2 /s Density 1.2 mg/cm3 Particle Radius 25 µm Residence time in GI 180 min Time required for complete dissolution Dissolution Number A function of drug release from formulation
  • 22. IVIVC expectations for immediate release products based on BCS Class Solubility Permeability Absorption rate control IVIVC expectations for Immediate release product I High High Gastric emptying IVIVC expected, if dissolution rate is slower than gastric emptying rate, otherwise limited or no correlations II Low High Dissolution IVIVC expected, if in vitro dissolution rate is similar to in vivo dissolution rate, unless dose is very high. III High Low Permeability Absorption (permeability) is rate determining and limited or no IVIVC with dissolution. IV Low Low Case by case Limited or no IVIVC is expected.
  • 23. High Solubility Low SolubilityHighPermeability Class 1 Abacavir Acetaminophen Acyclovirb AmilorideS,I Amitryptyline S,I Antipyrine Atropine Buspironec Caffeine Captopril ChloroquineS,I Chlorpheniramine Cyclophosphamide Desipramine Diazepam Diltiazem S,I Diphenhydramine Disopyramide Doxepin Doxycycline Enalapril Ephedrine Ergonovine Ethambutol Ethinyl Estradiol FluoxetineI Glucose ImipramineI Ketorolac Ketoprofen Labetolol LevodopaS Levofloxacin S LidocaineI Lomefloxacin Meperidine Metoprolol Metronidazole MidazolamS,I Minocycline Misoprostol Nifedipine S Phenobarbital Phenylalanine Prednisolone PrimaquineS Promazine Propranolol I Quinidine S,I Rosiglitazone Salicylic acid Theophylline Valproic acid Verapamil I Zidovudine Class 2 Amiodarone I AtorvastatinS, I AzithromycinS ,I Carbamazepine S,I Carvedilol Chlorpromazine I CisaprideS Ciprofloxacin S Cyclosporine S, I Danazol Dapsone Diclofenac Diflunisal Digoxin S Erythromycin S,I Flurbiprofen Glipizide GlyburideS,I Griseofulvin Ibuprofen Indinavir S Indomethacin Itraconazole S,I Ketoconazole I LansoprazoleI Lovastatin S,I Mebendazole Naproxen Nelfinavir S,I Ofloxacin Oxaprozin Phenazopyridine PhenytoinS Piroxicam Raloxifene S Ritonavir S,I Saquinavir S,I Sirolimus S Spironolactone I Tacrolimus S,I TalinololS Tamoxifen I Terfenadine I Warfarin
  • 24. High Solubility Low SolubilityLowPermeability Class 3 Acyclovir AmilorideS,I AmoxicillinS,I Atenolol Atropine Bisphosphonates Bidisomide Captopril Cefazolin Cetirizine Cimetidine S CiprofloxacinS Cloxacillin DicloxacillinS ErythromycinS,I Famotidine FexofenadineS Folinic acid Furosemide Ganciclovir Hydrochlorothiazide Lisinopril Metformin Methotrexate Nadolol PravastatinS Penicillins RanitidineS Tetracycline TrimethoprimS Valsartan Zalcitabine Class 4 Amphotericin B Chlorthalidone Chlorothiazide Colistin CiprofloxacinS Furosemide Hydrochlorothiazide Mebendazole Methotrexate Neomycin
  • 25. Applications of BCS in oral drug delivery technology  Achieve a target release profile associated with a particular pharmacokinetic and/or pharmacodynamic profile.  Formulation approaches include both control of release rate and certain physicochemical properties of drugs like pH-solubility profile of drug. Class I - High Permeability, High Solubility
  • 26. Class II - High Permeability, Low Solubility Micronisation, Addition of surfactants, Formulation as emulsions and microemulsions systems, Use of complexing agents like cyclodextrins
  • 27.  Require the technologies that address to fundamental limitations of absolute or regional permeability.  Peptides and proteins constitute the part of class III and the technologies handling such materials are on rise now days Class III - Low Permeability, High Solubility
  • 28. Class IV - Low Permeability, Low Solubility ♫Major challenge for development of drug delivery system and the route of choice for administering such drugs is parenteral (solubility enhancers.) ♫Fortunately, extreme examples are the exception rather than the rule and are rarely developed and reach the market
  • 29. Biowaiver  A biowaiver is an exemption from conducting human bioequivalence studies when the active ingredient(s) meet certain solubility and permeability criteria in vitro and when the dissolution profile of the dosage form meets the requirements for an "immediate" release dosage form.
  • 30. Waiver of In Vivo Bioequivalence Study based on Pharmaceutical Dosage Form (Solutions) Biopharmaceutics Classification System Dose. (Highest Strength should be tested)
  • 31. BCS BIOWAIVER  Biowaiver for  Rapid and similar dissolution.  High solubility &High permeability.  Wide therapeutic window.  Excipients used in dosage form used previously in approved IR solid dosage forms.
  • 32. REQUEST FOR BIOWAIVERS Data Supporting :- Rapid and Similar Dissolution High Permeability High Solubility
  • 33. Limitations of BCS as a Predictor of Drug Disposition Ω Permeability (90% absorption) is difficult to determine, and difficult to convince the regulatory agency . Ω There is little predictability for BCS classification drugs beyond Class 1 primarily due to the difficulty of determining and proving 90% absorption.  many drugs are misclassified (e.g. HIV protease inhibitors as Class 4 compounds)).
  • 34. Conclusion  BCS aims to provide a regulatory tool for replacing certain BE studies by accurate in- vitro dissolution tests..  This increased awareness of a proper biopharmaceutical characterization of new drugs may in the future result in drug molecules with a sufficiently high permeability, solubility and dissolution rate, and that will automatically increase the importance of the BCS as a regulatory tool over time
  • 35. References:  Draft guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/ active ingredients based on a biopharmaceutic classification system, february 1999, CDER/FDA.  Amidon G.L., Lennernas H., Shah V.P., Crison J.R.A., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12: 413-420 (1995).  Guidance for industry, immediate release solid oral dosage forms: scale up and post approval changes, november 1995, CDER/FDA.  Medicamento generico from website http://www.Anvisa.Go/.
  • 36.  Devane J., Oral drug delivery technology: addressing the solubility/ permeability paradigm, pharm. Technol. 68-74, november 1998  Amidon, G. L.,Lennernäs H., Shah V. P., And crisonj. R., A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharmaceutical research, 12: 413-420 (1995)  Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, FDA CDER, 1997 􀀛http://www.fda.gov/cder/guidance/1713bp1.pdf  Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, FDA CDER, August 2000 http://www.fda.gov/cder/guidance/3618fnl.htm